Kim CS, Martinez U, Mulvey E, et al. - Researchers sought to evaluate the effectiveness of the 4-week transtympanic dexamethasone perfusion treatment using the Silverstein MicroWick in patients with Meniere's disease. From January 2017 to December 2020, a self-reported questionnaire was designed and distributed to patients who received transtympanic dexamethasone perfusion treatment with the Silverstein MicroWick. Forty respondents were divided into two groups: Group 1 (n = 34) required no further procedure, and Group 2 (n = 6) required additional procedures for Meniere's disease. Transtympanic dexamethasone perfusion therapy with the MicroWick is a well-tolerated treatment option for Meniere's disease patients. According to the survey results, it has significant efficacy in reducing aural fullness and vertigo attacks in these patients. Prospective studies will be carried out to further establish its potential role in the successful management of Meniere's disease patients.